Skip to main content


Squeeze looks more likely for drug middlemen

By Wall Street Journal  
   March 25, 2019

Pharmaceuticals manufacturers are gradually disclosing more information about how drugs are priced. That is a problem for drug supply-chain companies and their investors. Eli Lilly said the price it was paid for its Humalog insulin averaged $135 a patient a month in 2018, down slightly from the 2014 average. Over that same period, however, the average list price—the sticker price before rebates and discounts are considered—rose more than 50%.

Full story

Get the latest on healthcare leadership in your inbox.